Atea Pharmaceuticals, Inc. (AVIR) Financial Analysis & Valuation | Quarter Chart
Atea Pharmaceuticals, Inc. (AVIR)
AVIRPrice: $2.9
Fair Value: 🔒
🔒score
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an antiviral drug candidate that is in Phase II clinical trial fo... more
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, deve... more
Description
Shares
| Market Cap | $230.13M | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | US | CEO | Jean-Pierre Sommadossi |
| IPO Date | 2020-10-30 | CAGR | — |
| Employees | 56 | Website | ateapharma.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | 11.09% | Total Yield | 11.09% |
AVIR chart loading...
Fundamentals
Technicals
| Enterprise Value | $215.02M | P/E Ratio | -2.02 |
| Forward P/E | -4.09 | PEG Ratio | — |
| P/S Ratio | 553.19 | P/B Ratio | 0.67 |
| P/CF Ratio | -2.08 | P/FCF Ratio | -1.97 |
| EPS | $-1.62 | EPS Growth 1Y | -14.49% |
| EPS Growth 3Y | -587.47% | EPS Growth 5Y | 188.89% |
| Revenue Growth 1Y | inf% | Gross Margin | -0.25% |
| Operating Margin | -376.48% | Profit Margin | -327.23% |
| ROE | -0.33% | ROA | -0.35% |
| ROCE | -0.42% | Current Ratio | 19.17 |
| Quick Ratio | 19.17 | Cash Ratio | 4.36 |
| Debt/Equity | 0 | Interest Coverage | — |
| Altman Z Score | 3.98 | Piotroski Score | 4 |